Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.74 USD
0.00 (-0.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.73 -0.01 (-1.08%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 81 - 100 ( 390 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Preliminary 4Q21 Xpovio Net Product Sales Exceed Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Nexpovio Licensing Agreement to Commercialize in Europe and Other Key Global Territories Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
New Partnership with Eye Towards NEXPOVIO EU Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Maintain Buy on LT Growth Prospects in China/SE Asia + Portfolio
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Data Update at ASH From the Phase 2 ESSENTIAL Study of Xpovio in Myelofibrosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2021 Day 1 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
First Patient Dosed in New Phase 2 Study of Xpovio in Previously Treated Myelofibrosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Complete Enrollment Achieved in the Phase 3 SIENDO Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
3Q21 Results; Xpovio 3Q21 Sales Exceed Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Dosing of First Patient Announced in Phase 2 Study of Eltanexor in HMA Refractory MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E